DocGo missed badly on the headline numbers. The company reported a third-quarter loss of $0.17 per share against a consensus estimate of a $0.04 loss, a 325.0% negative surprise. Revenue of $73.43 million missed the $76.97 million consensus by 4.6%. Management also lowered full-year revenue guidance for the second straight quarter, to about $300 million from $305-$310 million. That range had already been narrowed from $300-$315 million in the first quarter. The paradox is that this was also DocGo's best operating quarter in nearly two years. The miss and the margin improvement come from the same decision: management is shrinking the business to make it profitable, and the open question is whether it has enough time and cash to finish the job.

Earnings fell 54.5% year over year on the Earnings Whispers comparison basis. On a GAAP basis, the net loss attributable to shareholders was $0.17 per share, versus $0.28 a year ago. The prior-year GAAP figure was distorted in both directions: it included $16.7 million of goodwill and intangible impairments, partly offset by a $13.5 million tax benefit. Revenue grew 3.7%, the first year-over-year increase since mid-2023. The operating improvement is clearer in the sequential numbers:

• Adjusted gross margin rose to 33.3% from 30.5% in the second quarter.
• Adjusted EBITDA loss narrowed to $3.2 million, from $6.3 million in Q2 and $10.2 million in Q1.
• Adjusted SG&A fell to $28.7 million, close to the roughly $28 million level in management's breakeven model.

The gains are coming almost entirely from transportation. Medical transportation revenue reached a record $53.3 million, and the segment's adjusted gross margin climbed to 34.7% from 32.0% in Q2. That came despite fuel costs of about $4.18 per gallon. Excluding upstate New York, a market DocGo plans to exit by year-end, transport margin would have been 36.7%. Mobile Health is the weak spot:

• Revenue slid to $20.2 million from $21.4 million in Q2 and $23.6 million in Q1.
• Adjusted gross margin fell to 29.7% from 36.2% a year earlier.
• Care-in-the-home visits dropped 26% after management deliberately cut back outreach. The unit is on track for roughly a $5 million loss this year.
• SteadyMD is running $0.5-$1 million per quarter below internal expectations.

Record volumes in mobile phlebotomy (+15%) and virtual care (+12.5%) have not yet offset the pruning.

Management's argument is straightforward. About $240 million of the roughly $300 million revenue base is already adjusted EBITDA positive on a contribution basis. Lines that cannot clear that bar will be eliminated or redesigned. Roughly $20 million of a $60 million unprofitable basket is being cut, including about $10 million of upstate New York revenue that carried an estimated $3 million adjusted EBITDA loss. The reaffirmed full-year adjusted EBITDA guidance of a $17-$22 million loss implies something near breakeven in the fourth quarter, since the nine-month loss was already $19.8 million. Management also gave a preliminary framing of positive full-year 2027 adjusted EBITDA with reasonable top-line growth, but it is not formal guidance. Other catalysts include:

• The pending Hicuity Health acquisition, with about $65 million of trailing revenue not included in the guide.
• Collection of about $19 million in legacy municipal receivables.
• AI voice agents that cut in-home visit booking costs by more than 50%.
• A new care-gap-closure program with a large national payer in Pennsylvania.

Bears have legitimate ammunition, and most of it is about liquidity and leadership:

• Unrestricted cash fell to $19.1 million from $25.2 million in one quarter, with operating cash burn of $3.6 million.
• Management cautioned that positive operating cash flow could lag EBITDA breakeven by one to two quarters.
• Perceptive Advisors financing helps, but it is staged. The first $12.5 million tranche closed October 1, another $12.5 million depends on the Hicuity close, and $25 million more is tied to reaching $130 million of mobile health revenue. That is a demanding target given the segment's shrinking run rate.
• The company's own risk factors cite its ability to continue as a going concern and to maintain its Nasdaq listing.
• CEO Lee Bienstock's contract will not be renewed, and the board is seeking a successor for the 'next phase' of the transformation. Changing leaders mid-restructuring adds execution risk.

The market had already priced in a great deal of pain. Shares stood at $0.25 in the pre-report snapshot, down 57.2% from the $0.57 open after the August report. That leaves the stock about 56% below its 200-day moving average and only 17.5% above the 52-week low of $0.21 set on November 2. Investor sentiment moved from mildly negative (-0.16) to slightly positive (0.06) heading into the report. That suggests some investors were looking past the revenue erosion toward the margin story. Price and AVWAP trend readings, however, remain negative.

The bottom line is that DocGo delivered a clear miss and another revenue cut, but the quarter's real message is improving unit economics in a smaller, more focused business. Margins, SG&A, and the adjusted EBITDA loss all moved meaningfully in the right direction. Against that, cash is thin, the financing is conditional, Mobile Health is shrinking, and the CEO who designed the plan will not see it through. The turnaround has started to show up in the numbers, but the cash runway, not the margin trajectory, will likely decide whether it survives.